Neoplasms

Codes Discussed: C00-C96 (Malignant neoplasms code block), D00-D09 (In situ neoplasms code block), D10-D36 (Benign neoplasms code block), D3A (Benign neuroendocrine tumors category), D49 (Neoplasms of unspecified behavior category), C43 (Malignant melanoma of skin category), C44 (Other and unspecified malignant neoplasm of skin category), Z51 (Encounter for other aftercare and medical care category), C81-C85 (Lymphomas category range), C85.99 (Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites), T45.1X5 (Adverse effect of antineoplastic and immunosuppressive drugs category), D63.0 (Anemia in neoplastic disease), Z85 (Personal history of malignant neoplasm category), Z86.0 (Personal history of in-situ neoplasm, benign neoplasm, and neoplasm of uncertain behavior category), G89.3 (Neoplasm related pain), C80.0 (Disseminated malignant neoplasm, unspecified), C80.1 (Malignant neoplasm, unspecified), C84.7A (Anaplastic large cell lymphoma, ALK-negative, breast), Z12 (Encounter for screening for malignant neoplasm category), Z80 (Family history of primary malignant neoplasm category), Z40 (Encounter for prophylactic surgery category), C34.2 (Malignant neoplasm of middle lobe, bronchus or lung), C34.31 (Malignant neoplasm of lower lobe, right bronchus or lung), C34.81 (Malignant neoplasm of overlapping sites of right bronchus and lung), C34.91 (Malignant neoplasm of unspecified part of right bronchus or lung), C50.911 (Malignant neoplasm of unspecified site of right female breast), D64.9 (Anemia, unspecified), L76.02 (Intraoperative hemorrhage and hematoma of skin and subcutaneous tissue complicating other procedure), C16.9 (Malignant neoplasm of stomach, unspecified), C16.2 (Malignant neoplasm of body of stomach), L76.23 (Postprocedural hemorrhage of skin and subcutaneous tissue following other procedure), L76.22 (Postprocedural hemorrhage of skin and subcutaneous tissue following dermatologic procedure), L76.32 (Postprocedural hematoma of skin and subcutaneous tissue following other procedure), C78.7 (Secondary malignant neoplasm of liver and intrahepatic bile duct), C34.90 (Malignant neoplasm of unspecified part of unspecified bronchus or lung), C22.9 (Malignant neoplasm of liver, not specified as primary or secondary), Z85.118 (Personal history of other malignant neoplasm of bronchus and lung), C50.211 (Malignant neoplasm of upper-inner quadrant of right female breast), D25.2 (Subserosal leiomyoma of uterus), D25.0 (Submucous leiomyoma of uterus), D21.5 (Benign neoplasm of connective and other soft tissue of pelvis), D25.9 (Leiomyoma of uterus, unspecified), C61 (Malignant neoplasm of prostate), R33.8 (Other retention of urine), Z90.79 (Acquired absence of other genital organs), C62.90 (Malignant neoplasm of unspecified testis, unspecified whether descended or undescended), E86.0 (Dehydration), C79.51 (Secondary malignant neoplasm of bone), C34.12 (Malignant neoplasm of upper lobe, left bronchus or lung), C18.4 (Malignant neoplasm of transverse colon), C18.9 (Malignant neoplasm of colon, unspecified), D12.3 (Benign neoplasm of transverse colon), D03.72 (Melanoma in situ of left lower limb, including hip), Z85.820 (Personal history of malignant melanoma of skin), L97.229 (Non-pressure chronic ulcer of unspecified calf with unspecified severity), Z51.11 (Encounter for antineoplastic chemotherapy), C50.912 (Malignant neoplasm of unspecified site of left female breast), C78.00 (Secondary malignant neoplasm of unspecified lung), Z90.13 (Acquired absence of bilateral breasts and nipples), Z85.3 (Personal history of malignant neoplasm of breast), C50.911 (Malignant neoplasm of unspecified site of right female breast), M84.48XA (Pathological fracture, other site, initial encounter for fracture), Z90.12 (Acquired absence of left breast and nipple), D37.8 (Neoplasm of uncertain behavior of other specified digestive organs)

Topics Covered: ICD-10-CM neoplasm coding, ICD-10-CM Chapter 2 coding, cancer diagnosis coding, benign neoplasm coding, malignant neoplasm coding, carcinoma in situ coding, neoplasm of uncertain behavior coding, neoplasm of unspecified behavior coding, neoplasm morphology coding, neoplasm histology coding, neoplasm topography coding, anatomical site coding, neoplasm behavior groups, solid tumor coding, lymphatic neoplasm coding, hematopoietic neoplasm coding, leukemia coding, chronic lymphocytic leukemia, multiple myeloma coding, Hodgkin lymphoma coding, non-Hodgkin lymphoma coding, primary malignant neoplasm coding, secondary malignant neoplasm coding, metastatic cancer coding, direct extension coding, metastasis coding, metastatic to coding, extension to coding, provider query for neoplasm site, benign tumor coding, uncertain versus unspecified neoplasm behavior, pathology documentation for neoplasms, mass versus neoplasm coding, lesion versus neoplasm coding, neoplasm table coding, alphabetic index neoplasm coding, tabular verification, melanoma coding, malignant melanoma of skin coding, basal cell carcinoma coding, squamous cell carcinoma coding, adenocarcinoma coding, sarcoma coding, overlapping lesion coding, contiguous site neoplasm coding, overlapping lung malignancy coding, multiple tumors same organ coding, principal diagnosis neoplasm coding, primary site treatment coding, secondary site treatment coding, chemotherapy encounter coding, immunotherapy encounter coding, radiation therapy encounter coding, Z51 neoplastic therapy coding, extranodal lymphoma coding, neoplastic disease sequencing, neoplasm complication coding, anemia in neoplastic disease coding, chemotherapy adverse effect coding, immunotherapy adverse effect coding, radiation therapy adverse effect coding, current malignancy coding, history of malignancy coding, personal history of cancer coding, history of in-situ neoplasm coding, in remission coding, leukemia remission coding, malignant plasma cell neoplasm remission coding, neoplasm-related pain coding, cancer pain management coding, disseminated malignant neoplasm coding, cancer unspecified coding, unknown primary malignancy coding, metastatic disease with unknown primary site, surgical removal of neoplasm coding, chemotherapy after surgery coding, radiation after surgery coding, complications during neoplastic therapy, nausea and vomiting after chemotherapy, breast implant associated anaplastic large cell lymphoma coding, BIA-ALCL coding, breast implant lymphoma coding, extent of malignancy workup coding, tumor evaluation coding, biopsy for neoplasm coding, paracentesis for malignancy coding, thoracentesis for malignancy coding, cancer screening coding, screening versus diagnostic examination, family history of malignancy coding, aftercare for neoplastic disease, follow-up after cancer treatment, prophylactic organ removal coding, prophylactic mastectomy coding, cancer susceptibility coding, prophylactic surgery coding, lung cancer coding, breast cancer coding, liver metastasis coding, bone metastasis coding, pulmonary metastasis coding, prostate cancer coding, colon adenocarcinoma coding, transverse colon cancer coding, uterine leiomyoma coding, melanoma in situ coding, pancreatic neoplasm of uncertain behavior coding, pathological fracture due to neoplasm coding, mastectomy status coding, orchiectomy status coding, Code Purple practice, Code Red assessment, neoplasm coding scenarios